FibroGen, Inc. Revenue 2020–2025
FibroGen, Inc. annual/quarterly revenue history and growth rate from 2020 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- FibroGen, Inc. revenue for the quarter ending March 31, 2026 was 3.7 M, a 36.47% increase year-over-year.
- FibroGen, Inc. revenue for the twelve months ending March 31, 2026 was 7.4 M.
- FibroGen, Inc. annual revenue for 2025 was 6.4 M, a 78.26% decrease from 2024.
- FibroGen, Inc. annual revenue for 2024 was 29.6 M, a 79.95% decrease from 2023.
- FibroGen, Inc. annual revenue for 2023 was 147.8 M, a 4.99% increase from 2022.
- FibroGen, Inc. annual revenue for 2022 was 140.7 M.
FibroGen, Inc. (KYNB) — Frequently Asked Questions
FibroGen, Inc. (KYNB) is a publicly traded US company. It has a market capitalization of $27M. In fiscal 2025 it reported revenue of $6M and net income of $183M. Explore KYNB's stock price, financial statements, earnings history, margins and key ratios below.
What is FibroGen, Inc.'s market cap?
FibroGen, Inc. (KYNB) has a market capitalization of $27M.
What is the KYNB stock price?
KYNB trades at $6.69.
How much revenue does FibroGen, Inc. make?
FibroGen, Inc. reported revenue of $6M in fiscal 2025.
Is KYNB profitable?
In fiscal 2025, FibroGen, Inc. reported net income of $183M.
What is KYNB's P/E ratio?
Based on diluted EPS, KYNB has a price-to-earnings (P/E) ratio of about 0.1.